Lunaphore Launches Its First Product LabSatTM
7.2.2019 13:30:00 EET | Business Wire | Press release
Lunaphore Technologies SA, a Swiss medtech firm developing innovative next-generation equipment for cancer research and tissue diagnostics, announces that its first product, LabSatTM for research applications, is now released for commercialization.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190207005294/en/
Lunaphore's new product LabSat (Photo: Business Wire)
The CE-marked instrument is in compliance with all applicable product health, safety and environmental regulations of the European Union and will be available in most European countries.
LabSatTM is the first solution in Lunaphore’s pipeline to reach the market since the foundation of the company. The system consists of a single-slide, automated reagent delivery system performing immunohistochemistry (IHC) tests on tissue samples within 10 to 30 minutes. The breakthrough speed performance of the device is achieved thanks to a novel microfluidic tissue processor lying at the core of Lunaphore’s innovation. This patented technology enables high precision tissue staining, with a drastic reduction of reagent incubation times.
Lunaphore’s Founder and CEO, Ata Tuna Ciftlik, said: “This very first product aims to bring our breakthrough technology to the hands of our customers. We believe that its precision and speed will open a multitude of staining possibilities for the users,” and added: “In parallel, we’re working on the next product iterations to answer the needs of customers with greater needs of automation as well as a wider portfolio of applications.”
At the moment, the company is developing as well a solution for the In-Vitro Diagnostics field, which aims to launch in the near future.
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company developing next generation tissue autostainers. The award-winning technology based on microfluidics is called FFeX (Fast Fluidic Exchange). It aims to perform assays much faster than standard techniques and has demonstrated good results in tests with cancer patient samples. Lunaphore was founded in 2014 with the vision of bringing –omics like approaches to tissue diagnostics and has been recognized as one of the most innovative companies nationally and internationally.
About immunohistochemistry
IHC staining is a technique that involves the use of antibodies to detect the presence of specific cancer biomarkers on a tissue sample. IHC is the most frequently performed biomarker test in routine cancer diagnostics* following a biopsy procedure, as well as common test in immuno-oncology research. During an IHC test, the tissue sample is stained with labelled antibodies - producing a tissue coloring visible with a microscope- that will signal the presence and localization of specific cancer biomarkers, in order to support clinicians and researchers in the identification of specific cancer types.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190207005294/en/
Contact information
Irene Tamayo
Lunaphore Corporate Communications
Email: communications@lunaphore.com
Phone:
+41 21 353 58 22
Andrea Büchler
Lunaphore Finance and Business Development
Email:
andrea.buechler@lunaphore.com
Phone
+41 79 598 40 73
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency 1 , and Core EBITDA 2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 08:00:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new product launches across Galderma’s full portfoli
The Estée Lauder Companies and Forest Essentials to Enter a New Chapter in Their Long-Term Partnership5.3.2026 07:45:00 EET | Press release
The Estée Lauder Companies Inc. (NYSE: EL) announced today that it has entered into an agreement, subject to regulatory approvals, to acquire the remaining interests in Forest Essentials, the Indian beauty brand grounded in the science of modern Luxurious Ayurveda. Building on a trusted 18-year partnership, this milestone celebrates The Estée Lauder Companies’ long-term commitment to nurturing and growing this extraordinary Indian brand and to expanding its consumer reach globally. Today’s announcement reflects the company’s strong confidence in Forest Essentials’ highly trusted brand equity, its vertically integrated capabilities, and its sustainability ethos. The transaction is expected to close in the second half of calendar year 2026 and follows The Estée Lauder Companies’ minority investment in Forest Essentials, initially made in 2008 and increased to 49% in 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026030494
Kinaxis Announces Departure of Chief Financial Officer5.3.2026 00:00:00 EET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that Blaine Fitzgerald, Chief Financial Officer (CFO), has advisedof his intention to step down from his role to pursue a new career opportunity with a private company outside the supply chain software space. A search will begin for a new CFO immediately. Fitzgerald remains with the company as CFO through May 8, following the company’s first quarter 2026 earnings call, to support a smooth transition. “We are grateful for Blaine’s leadership and contributions over the past six years. He has played a key role in strengthening our financial foundation, building out the financial leadership team, and advancing our AI strategy. Thanks to the depth and capability of our Senior Leadership Team, we remain well-positioned for continued success as we begin the search for our next finance leader,” said Razat Gaurav, Chief Executive Officer, Kinaxis. “We wish Blaine every success as he embarks on his next chapt
IFF Declares Dividend for First Quarter 20264.3.2026 23:15:00 EET | Press release
IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 10, 2026 to shareholders of record as of March 20, 2026. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20260304579613/en/
Armis Named a Leader for Second Consecutive Year in 2026 Gartner® Magic Quadrant™ for CPS Protection Platforms4.3.2026 17:12:00 EET | Press release
Armis, the cyber exposure management & security company, today announced that it has been named a Leader in the 2026 Gartner Magic Quadrant for CPS Protection Platforms for the second consecutive year. “In an era of agentic AI, the security of our cyber-physical systems has become a strategic imperative for enterprises and governments globally; it is a pivotal pillar of global stability,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “We believe this back-to-back recognition from Gartner reflects our continued commitment to helping organizations secure the complex, critical world of CPS and reinforces the strength of our unified, proactive platform approach. Our innovation pipeline, which is aligned with our customers' needs, will continue to prioritize protecting critical environments to keep society safe and secure.” Armis was named a Leader in this report among the 13 vendors that were evaluated. Armis Centrix™, the Armis Cyber Exposure Management Platform, was evaluated within
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom